InVision Precision Cardiac Amyloid vs Volta AF-Xplorer

InVision Precision Cardiac Amyloid is designed to integrate seamlessly into existing echocardiography workflows, processing studies in the background with results often ready before the scan is finished. This approach minimizes disruption and additional steps for clinicians. Volta AF-Xplorer, while offering a simple user interface and compatibility with existing EP lab hardware, still requires active engagement during a procedure to guide ablation.

InVision Precision Cardiac Amyloid addresses a critical need for earlier detection of cardiac amyloidosis, a life-threatening and often underdiagnosed disease, with approved therapies that can reduce mortality and improve quality of life. It has strong clinical validation, including peer-reviewed publications in JAMA Cardiology and JACC: Advances, and FDA clearance as a diagnostic aid for adults aged 65 and older. Volta AF-Xplorer aims to improve outcomes for complex atrial fibrillation ablation procedures by providing real-time guidance, and has shown promising findings in clinical trials.

InVision Precision Cardiac Amyloid has transparent pricing details with a New Medicare NTAP approved for up to $2,275 per eligible inpatient stay, effective October 1, 2026, and a CPT Category III code for outpatient use. This clear reimbursement pathway demonstrates a strong value proposition for healthcare systems. Volta AF-Xplorer requires contacting for pricing, which offers less transparency.

InVision Precision Cardiac Amyloid offers flexible deployment options (cloud or on-premise) and is designed for health systems, integrating with existing imaging systems. Its clear reimbursement pathways (NTAP and CPT code) further enhance its readiness for enterprise adoption. Volta AF-Xplorer also integrates with existing EP lab hardware, but its enterprise readiness is less explicitly detailed regarding deployment and broader financial frameworks.

Both tools demonstrate significant innovation in their respective fields. InVision Precision Cardiac Amyloid uses AI to detect a rare and often missed disease from routine echocardiograms, integrating information across multiple views for a holistic assessment. Volta AF-Xplorer provides real-time AI-assisted mapping and decision support during complex ablation procedures, with features like automated tagging and a dispersion indicator. Both leverage advanced AI algorithms trained on large datasets to address complex cardiac conditions.

Both companies provide evidence of support and documentation. InVision Medical Technology highlights peer-reviewed publications and FDA clearance, indicating robust scientific backing. Volta Medical provides access to clinical evidence and user manuals directly on their website. Without more specific details on the breadth and accessibility of their support resources (e.g., training programs, dedicated support teams, online knowledge bases), it is difficult to definitively choose a winner.